Antibody producing human-human hybridomas. I. Technical aspects.
Technical aspects of generation of antibody-secreting human-human hybridomas are evaluated as based on 100 human-human fusions with a human B-lymphoma cell line (RH-L4) or the SKO-007 myeloma cell line as malignant fusion partners, and compared with similar fusion conditions in the mouse hybridoma system. The yield of hybrids was significantly lower when normal peripheral blood lymphocytes were used as fusion partners as compared with spleen lymphocytes, but could be substantially improved by increasing the amount of mitotic active B-lymphocytes by mitogen stimulation of the lymphocytes, preferably in HAT medium, prior to fusion. Furthermore, human hybrids grew slower and had a higher degree of chromosomal instability than usually observed in the mouse hybridoma system. Thus, out of 72 fusions, only 3 stable hybrids with antibody production against a predefined antigen were established. The importance of improved sources of human B-lymphocytes for human-human hybridoma production is discussed and methods of obtaining such improvement suggested.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000302:isolation & purification*; D001402:B-Lymphocytes / Q000276:immunology; D002459:Cell Fusion; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006825:Hybridomas / Q000276:immunology*; D007158:Immunologic Techniques; D007621:Karyotyping; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D010954:Plasmacytoma / Q000276:immunology
D000911:Antibodies, Monoclonal